Results 61 to 70 of about 45,588 (281)
Ovarian macrophage depletion reverses OHSS resistance in estrildid finches and exacerbates OHSS symptoms in rats. Activating macrophage GPR183 alleviates OHSS by reducing pro‐inflammatory factors, increasing immunomodulatory molecules, remodeling CD44/SDC4‐mediated communication, and restoring immune homeostasis.
Xiaofei Yan +11 more
wiley +1 more source
Phosphodiesterase Type 5 Inhibitor Use and Hearing Impairment [PDF]
To compare use of phosphodiesterase type 5 inhibitors (PDE-5i) between participants with and without self-reported hearing impairment using logistic regression, with and without adjustment for potentially confounding sociodemographic, behavioral, and health-related characteristics.Cross-sectional.United States.A population-based sample of 11 525 men 40
openaire +2 more sources
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo +16 more
wiley +1 more source
Tadalafil (TD) is a phosphodiesterase type 5 (PDE-5) inhibitor that has gained attention for its wound healing properties. In this study, a TD-loaded hydrogel was prepared and characterized, and its wound-healing efficacy was evaluated.
Anita Sadat Haji Seyed Javadi Pajouhi +5 more
doaj +1 more source
A novel epitranscriptomic mechanism in rheumatoid arthritis is uncovered: NSUN2 promotes disease via m5C‐dependent stabilization of ICMT mRNA, fueling the migration and invasion of pathogenic RA FLS. Targeting this axis with engineered nanoparticles (Ce/SAA NPs) effectively inhibits disease progression, presenting a precise therapeutic strategy ...
Ruiru Li +15 more
wiley +1 more source
A label-free LC/MS-based enzymatic activity assay for the detection of PDE5A inhibitors
Phosphodiesterase type 5 (PDE5), a cyclic nucleotide phosphodiesterase, controls the duration of the cyclic guanosine monophosphate (cGMP) signal by hydrolyzing cGMP to GMP.
Yufeng Ma +9 more
doaj +1 more source
Management of erectile dysfunction with a novel orodispersible formulation of the PDE-5 inhibitor vardenafil [PDF]
Erectile dysfunction (ED) is a medical condition which can affect men of all ages. As men live longer and the prevalence of cardiovascular disease and diabetes continue to increase, the problem of ED will become more prominent.
Cordina, Maria
core
Off-Label Use of Phosphodiesterase Type 5 Inhibitor Erectile Dysfunction Medication to Enhance Sex Among Gay and Bisexual Men in Australia: Results From the FLUX Study [PDF]
© 2017 International Society for Sexual Medicine Background Gay and bisexual men (GBM) use oral erectile dysfunction medications (EDMs) often with little evidence of medical indication necessitating their use. Aim To investigate the prevalence, contexts,
Toby Lea +11 more
core +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study): A Randomized Controlled Trial [PDF]
Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have limitations.
Keogh AM +12 more
core +1 more source

